Palbociclib Extends Survival in Advanced Breast Cancer.
Författaruppgift saknas
Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-nb2015-083 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för palbociclib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
10 träffarPalbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M, PALOMA3 Study Group.
N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1505270Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S.
Leuk Lymphoma · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.3109/10428194.2015.1030641Palbociclib: first global approval.
Dhillon S.
Drugs · review; journal article · DOI 10.1007/s40265-015-0379-9CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C, Boyson CA, Di Liberto M, Huang X, Hannah J, Dorn DC, Moore MA, Chen-Kiang S, Zhou P.
Cancer Res · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-14-2486Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Vaughn DJ, Hwang WT, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ.
Cancer · clinical trial, phase ii; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1002/cncr.29213The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ.
Lancet Oncol · video-audio media; clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/s1470-2045(14)71159-3The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
Altenburg JD, Farag SS.
Expert Opin Investig Drugs · review; journal article; research support, n.i.h., extramural · DOI 10.1517/13543784.2015.993753CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P.
Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-14-2258PD0332991 (palbociclib) for treatment of pediatric intracranial growing teratoma syndrome.
Schultz KA, Petronio J, Bendel A, Patterson R, Vaughn DJ.
Pediatr Blood Cancer · research support, non-u.s. gov't; journal article; case reports · DOI 10.1002/pbc.25338